Approach to the Assessment and Management of Adult Patients With Atopic Dermatitis: A Consensus Document. Section IV: Treatment Options for the Management of Atopic Dermatitis
Restricted accessResearch articleFirst published online November, 2018
Approach to the Assessment and Management of Adult Patients With Atopic Dermatitis: A Consensus Document. Section IV: Treatment Options for the Management of Atopic Dermatitis
The objectives of therapy for atopic dermatitis (AD) are to reduce skin inflammation and pruritus, restore skin barrier function, and improve quality of life (QoL). Treatments can be classified as moisturizing and basic care, topical therapy, phototherapy, and systemic therapy. In this review, we summarize the treatments for AD and recommendations for their use.
LyndeCWBourcierMGooderhamMet al. A treatment algorithm for moderate to severe atopic dermatitis in adults. J Cutan Med Surg. 2018;22(1):78-83.
2.
BoguniewiczMAlexisAFBeckLAet al. Expert perspectives on management of moderate-to-severe atopic dermatitis: a multidisciplinary consensus addressing current and emerging therapies. J Allergy Clin Immunol Pract. 2017;5(6):1519-1531.
3.
SimpsonELBruin-WellerMFlohrCet al. When does atopic dermatitis warrant systemic therapy? Recommendations from an expert panel of the International Eczema Council. J Am Acad Dermatol. 2017;77(4):623-633.
4.
RingJAlomarABieberTet al. Guidelines for treatment of atopic eczema (atopic dermatitis) part I. J Eur Acad Dermatol Venereol. 2012;26(8):1045-1060.
5.
WollenbergABarbarotSBieberTet al. Consensus-based European guidelines for treatment of atopic eczema (atopic dermatitis) in adults and children: part I. J Eur Acad Dermatol Venereol. 2018;32(5):657-682.
6.
EichenfieldLFAhluwaliaJWaldmanABorokJUdkoffJBoguniewiczM.Current guidelines for the evaluation and management of atopic dermatitis: a comparison of the Joint Task Force Practice Parameter and American Academy of Dermatology guidelines. J Allergy Clin Immunol. 2017;139(4):S49-S57.
7.
SimpsonELChalmersJRHanifinJMet al. Emollient enhancement of the skin barrier from birth offers effective atopic dermatitis prevention. J Allergy Clin Immunol. 2014;134(4):818-823.
8.
GrimaltRMengeaudVCambazardF.The steroid-sparing effect of an emollient therapy in infants with atopic dermatitis: a randomized controlled study. Dermatology. 2007;214(1):61-67.
9.
EichenfieldLFTomWLBergerTGet al. Guidelines of care for the management of atopic dermatitis: Section 2. Management and treatment of atopic dermatitis with topical therapies. J Am Acad Dermatol. 2014;71(1):116-132.
10.
HonKKungJSCNgWGGLeungTF.Emollient treatment of atopic dermatitis: latest evidence and clinical considerations. Drugs Context. 2018;7:212530.
11.
SilverbergNB.Selected active naturals for atopic dermatitis: atopic dermatitis part 1. Clin Dermatol. 2017;35(4):383-386.
CzarnowickiTMalajianDKhattriSet al. Petrolatum: barrier repair and antimicrobial responses underlying this “inert” moisturizer. J Allergy Clin Immunol. 2016;137(4):1091-1102.e7.
14.
HlelaCLunjaniNGumedzeFKakandeBKhumaloN.Affordable moisturisers are effective in atopic eczema: a randomised controlled trial. S Afr Med J. 2015;105(9):780-784.
15.
HonKChingGLeungTChoiCLeeKNgP.Estimating emollient usage in patients with eczema. Clin Exp Dermatol. 2009;35(1):22-26.
ChopraRVakhariaPPSacotteRSilverbergJI.Efficacy of bleach baths in reducing severity of atopic dermatitis: a systematic review and meta-analysis. Ann Allergy Asthma Immunol. 2017;119(5):435-440.
18.
MaybaJNGooderhamMJ.Review of atopic dermatitis and topical therapies. J Cutan Med Surg. 2017;21(3):227-236.
19.
Berth-JonesJDamstraRJGolschSet al. Twice weekly fluticasone propionate added to emollient maintenance treatment to reduce risk of relapse in atopic dermatitis: randomised, double blind, parallel group study. BMJ. 2003;326(7403):1367.
20.
FaergemannJChristensenOSjovallPet al. An open study of efficacy and safety of long-term treatment with mometasone furoate fatty cream in the treatment of adult patients with atopic dermatitis. J Eur Acad Dermatol Venereol. 2000;14(5):393-396.
21.
HanifinJGuptaARajagopalanR.Intermittent dosing of fluticasone propionate cream for reducing the risk of relapse in atopic dermatitis patients. Br J Dermatol. 2002;147(3):528-537.
22.
JanmohamedSROranjeAPDevillersACet al. The proactive wet-wrap method with diluted corticosteroids versus emollients in children with atopic dermatitis: a prospective, randomized, double-blind, placebo-controlled trial. J Am Acad Dermatol. 2014;70(6):1076-1082.
23.
WolkerstorferAVisserRLWaardFBSpekVMulderPGHOranjeAP.Efficacy and safety of wet-wrap dressings in children with severe atopic dermatitis: influence of corticosteroid dilution. Br J Dermatol. 2000;143(5):999-1004.
24.
StalderJFAubertHAnthoineEet al. Topical corticosteroid phobia in atopic dermatitis: International feasibility study of the TOPICOP score. Allergy. 2017;72(11):1713-1719.
25.
LeeJHerYKimCKimS.Topical corticosteroid phobia among parents of children with atopic eczema in Korea. Ann Dermatol. 2015;27(5):499-506.
26.
StormABenfeldtEAndersenSSerupJ.A prospective study of patient adherence to topical treatments: 95% of patients underdose. J Am Acad Dermatol. 2008;59(6):975-980.
27.
PallerASLebwohlMFleischerABet al. Tacrolimus ointment is more effective than pimecrolimus cream with a similar safety profile in the treatment of atopic dermatitis: results from 3 randomized, comparative studies. J Am Acad Dermatol. 2005;52(5):810-822.
28.
FleischerABJrAbramovitsWBrenemanDJaraczE.Tacrolimus ointment is more effective than pimecrolimus cream in adult patients with moderate to very severe atopic dermatitis. J Dermatolog Treat. 2009;18(3):151-157.
29.
ArellanoFMWentworthCEAranaAFernándezCPaulCF.Risk of lymphoma following exposure to calcineurin inhibitors and topical steroids in patients with atopic dermatitis. J Invest Dermatol. 2007;127(4):808-816.
30.
LegendreLBarnetcheTMazereeuw-HautierJMeyerNMurrellDPaulC.Risk of lymphoma in patients with atopic dermatitis and the role of topical treatment: a systematic review and meta-analysis. J Am Acad Dermatol. 2015;72(6):992-1002.
31.
CastellsagueJKuiperJGPottegårdAet al. A cohort study on the risk of lymphoma and skin cancer in users of topical tacrolimus, pimecrolimus, and corticosteroids (Joint European Longitudinal Lymphoma and Skin Cancer Evaluation—JOELLE study). Clin Epidemiol. 2018;10:299-310.
32.
SchneeweissSDohertyMZhuSet al. Topical treatments with pimecrolimus, tacrolimus and medium- to high-potency corticosteroids, and risk of lymphoma. Dermatology. 2009;219(1):7-21.
33.
TennisPGelfandJMRothmanKJ.Evaluation of cancer risk related to atopic dermatitis and use of topical calcineurin inhibitors. Br J Dermatol. 2011;165(3):465-473.
34.
MargolisDJAbuabaraKHoffstadOJWanJRaimondoDBilkerWB.Association between malignancy and topical use of pimecrolimus. JAMA Dermatol. 2015;151(6):594-599.
35.
GeorgeSBilslandDJohnsonBFergusonJ.Narrow-band (TL-01) UVB air-conditioned phototherapy for chronic severe adult atopic dermatitis. Br J Dermatol. 1993;128(1):49-56.
36.
ReynoldsNFranklinVGrayJDiffeyBFarrP.Narrow-band ultraviolet B and broad-band ultraviolet A phototherapy in adult atopic eczema: a randomised controlled trial. Lancet. 2001;357(9273):2012-2016.
37.
HeinlinJSchiffner-RoheJSchiffnerRet al. A first prospective randomized controlled trial on the efficacy and safety of synchronous balneophototherapy vs. narrow-band UVB monotherapy for atopic dermatitis. J Eur Acad Dermatol Venereol. 2011;25(7):765-773.
38.
LeeEKooJBergerT.UVB phototherapy and skin cancer risk: a review of the literature. Int J Dermatol. 2005;44(5):355-360.
39.
TzanevaSSeeberASchwaigerMHönigsmannHTanewA.High-dose versus medium-dose UVA1 phototherapy for patients with severe generalized atopic dermatitis. J Am Acad Dermatol. 2001;45(4):503-507.
40.
GooderhamMLyndeWPappKet al. Review of systemic treatment options for adult atopic dermatitis. J Cutan Med Surg. 2017;21(1):31-39.
41.
DruckerAMEyerichKde Bruin-WellerMSet al. Use of systemic corticosteroids for atopic dermatitis: International Eczema Council consensus statement. Br J Dermatol. 2018;178(3):768-775.
42.
SchmittJSchäkelKFölster-HolstRet al.Prednisolonevs.ciclosporin for severe adult eczema: an investigator-initiated double-blind placebo-controlled multicentre trial. Br J Dermatol. 2010;162(3):661-668.
43.
MaybaJGooderhamM. Oral agents for atopic dermatitis: current and in development. In: YamauchiP ed. Biologic and Systemic Agents in Dermatology. Cham, Switzerland: Springer; 2018:319-330.
44.
YuSHDruckerAMLebwohlMSilverbergJI.A systematic review of the safety and efficacy of systemic corticosteroids in atopic dermatitis. J Am Acad Dermatol. 2018;78(4):733-740e.11.
45.
SidburyRDavisDMCohenDEet al. Guidelines of care for the management of atopic dermatitis: Section 3. Management and treatment with phototherapy and systemic agents. J Am Acad Dermatol. 2014;71(2):327-349.
46.
WeatherheadSCWahieSReynoldsNJMeggittSJ.An open-label, dose-ranging study of methotrexate for moderate-to-severe adult atopic eczema. Br J Dermatol. 2007;156(2):346-351.
47.
SchramMRoekevischELeeflangMBosJSchmittJSpulsP.A randomized trial of methotrexate versus azathioprine for severe atopic eczema. J Allergy Clin Immunol. 2011;128(2):353-359.
48.
GerbensLAAHamannSABrouwerMWDRoekevischELeeflangMMGSpulsPI. Methotrexate and azathioprine for severe atopic dermatitis: a 5-year follow-up study of a randomized controlled trial. Br J Dermatol. 2018:178(6):1288-1296.
49.
GoujonCViguierMStaumont-SalléDet al. Methotrexate versus cyclosporine in adults with moderate-to-severe atopic dermatitis: a phase III randomized noninferiority trial. J Allergy Clin Immunol Pract. 2018;6(2):562-569.e3.
50.
RoekevischESpulsPKuesterDLimpensJSchmittJ.Efficacy and safety of systemic treatments for moderate-to-severe atopic dermatitis: a systematic review. J Allergy Clin Immunol. 2014;133(2):429-438.
51.
MeggittSJGrayJCReynoldsNJ.Azathioprine dosed by thiopurine methyltransferase activity for moderate-to-severe atopic eczema: a double-blind, randomised controlled trial. Lancet. 2006;367(9513):839-846.
52.
MeggittSReynoldsN.Azathioprine for atopic dermatitis. Clin Exp Dermatol. 2001;26(5):369-375.
53.
MurrayMCohenJ.Mycophenolate mofetil therapy for moderate to severe atopic dermatitis. Clin Exp Dermatol. 2007;32(1):23-27.
54.
HaeckIMKnolMJten BergeOvan VelsenSde Bruin-WellerMSBruijnzeel-KoomenC.Enteric-coated mycophenolate sodium versus cyclosporin A as long-term treatment in adult patients with severe atopic dermatitis: a randomized controlled trial. J Am Acad Dermatol. 2011;64(6):1074-1084.
55.
SimpsonELBieberTGuttman-YasskyEet al. Two phase 3 trials of dupilumab versus placebo in atopic dermatitis. N Engl J Med. 2016;375:2335-2348.
56.
BlauveltAde Bruin-WellerMGooderhamMet al. Long-term management of moderate-to-severe atopic dermatitis with dupilumab and concomitant topical corticosteroids (LIBERTY AD CHRONOS): a 1-year, randomised, double-blinded, placebo-controlled, phase 3 trial. Lancet. 2017;389(10086):2287-2303.
57.
de Bruin-WellerMThaciDSmithCet al. Dupilumab with concomitant topical corticosteroid treatment in adults with atopic dermatitis with an inadequate response or intolerance to ciclosporin A or when this treatment is medically inadvisable: a placebo-controlled, randomized phase III clinical trial (LIBERTY AD CAFE). Br J Dermatol. 2018;178(5):1083-1101.
58.
NygaardUVestergaardCDeleuranM.Emerging treatment options in atopic dermatitis: systemic therapies. Dermatology. 2017;233(5):344-357.
59.
LeeDEClarkAKTranKAShiVY.New and emerging targeted systemic therapies: a new era for atopic dermatitis. J Dermatolog Treat. 2018;29(4):364-374.
60.
PallerAKabashimaKBieberT.Therapeutic pipeline for atopic dermatitis: end of the drought?J Allergy Clin Immunol. 2017;140(3):633-643.
61.
WollenbergAHowellMDGuttman-YasskyEet al. Treatment of atopic dermatitis with tralokinumab, an anti-IL-13 monoclonal antibody [published online June 12, 2018]. J Allergy Clin Immunol.
62.
SimpsonELFlohrCEichenfieldLFet al. Efficacy and safety of lebrikizumab (an anti-IL-13 monoclonal antibody) in adults with moderate-to-severe atopic dermatitis inadequately controlled by topical corticosteroids: a randomized, placebo-controlled phase II trial (TREBLE). J Am Acad Dermatol. 2018;78(5):863-871.e11.
63.
RuzickaTHanifinJMFurueMet al. Anti-interleukin-31 receptor A antibody for atopic dermatitis. N Engl J Med. 2017;376(9):826-835.
64.
Guttman-YasskyEBrunnerPNeumannAet al. Efficacy and safety of fezakinumab (an IL-22 monoclonal antibody) in adults with moderate-to-severe atopic dermatitis inadequately controlled by conventional treatments: a randomized, double-blind, phase 2a trial. J Am Acad Dermatol. 2018;78(5):872-881.e6.
65.
Guttman-YasskyESilverbergJINemotoOet al. Baricitinib in adult patients with moderate-to-severe atopic dermatitis: a phase 2 parallel, double-blinded, randomized placebo-controlled multiple-dose study [published online February 1, 2018]. J Am Acad Dermatol.
66.
CotterDGSchairerDEichenfieldL.Emerging therapies for atopic dermatitis: JAK inhibitors. J Am Acad Dermatol. 2018;78(3)(suppl 1):S53-S62.
67.
GooderhamMFormanSBissonnetteRet al. PF-04965842, a JAK1 inhibitor, for treatment of atopic dermatitis: a 12-week, randomised, double-blind, placebo-controlled phase 2 clinical trial. Paper presented at: 26th EADV Congress; September 13-17, 2017; Geneva, Switzerland.
SchneiderLTillesSLioPet al. Atopic dermatitis: a practice parameter update 2012. J Allergy Clin Immunol. 2013;131(2):295-9.e1-27.
70.
RingJAlomarABieberTet al. Guidelines for treatment of atopic eczema (atopic dermatitis) part II. J Eur Acad Dermatol Venereol. 2012;26(9):1176-1193.
71.
HeddleRJSoothillJFBulpittCJAthertonDJ.Combined oral and nasal beclomethasone diproprionate in children with atopic eczema: a randomised controlled trial. Br Med J Clin Res Ed. 1984;289:651-654.
72.
La RosaMRannoCMusarraIGuglielmoFCorriasABellantiJA. Double-blind study of cetirizine in atopic eczema in children. Ann Allergy. 1994;73:117-122.
73.
GalliEChiniLMoscheseVet al. Methylprednisolone bolus: a novel therapy for severe atopic dermatitis. Acta Paediatr. 1994;83:315-317.
74.
MegnaMNapolitanoMPatrunoCet al. Systemic treatment of adult atopic dermatitis: a review. Dermatol Ther (Heidelb). 2017;7:1-23.
75.
MurphyLAthertonD.Azathioprine in severe childhood eczema: value of TPMT as a predictor of outcome and safety in treatment. Br J Dermatol. 2001;144:927.
76.
WollenbergAHowellMDGuttman-YasskyEet al. A phase 2b dose-ranging efficacy and safety study of tralokinumab in adult patients with moderate to severe atopic dermatitis (AD). J Amer Acad Dematol. 2017;76(6)(suppl 1):AB20.
77.
VakhariaPPSilverbergJI.New therapies for atopic dermatitis: additional treatment classes. J Am Acad Dermatol. 2018;78(3)(suppl 1):S76-S83.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
